[go: up one dir, main page]

WO2024092106A3 - N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof - Google Patents

N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof Download PDF

Info

Publication number
WO2024092106A3
WO2024092106A3 PCT/US2023/077879 US2023077879W WO2024092106A3 WO 2024092106 A3 WO2024092106 A3 WO 2024092106A3 US 2023077879 W US2023077879 W US 2023077879W WO 2024092106 A3 WO2024092106 A3 WO 2024092106A3
Authority
WO
WIPO (PCT)
Prior art keywords
dmt
methods
dimethyltryptamine
making
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/077879
Other languages
French (fr)
Other versions
WO2024092106A2 (en
Inventor
Srinivas G Rao
Glen Short
Majed Fawaz
Prerak Patel
Santnu PATEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atai Therapeutics Inc
Original Assignee
Atai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/974,443 external-priority patent/US20230136824A1/en
Application filed by Atai Therapeutics Inc filed Critical Atai Therapeutics Inc
Priority to AU2023367107A priority Critical patent/AU2023367107A1/en
Priority to CA3267555A priority patent/CA3267555A1/en
Priority to EP23883743.9A priority patent/EP4608395A2/en
Publication of WO2024092106A2 publication Critical patent/WO2024092106A2/en
Publication of WO2024092106A3 publication Critical patent/WO2024092106A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical compositions including an amorphous N-N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt or prodrug thereof, and a polymeric carrier are described. These compositions are suitable for buccal or sublingual administration to a patient. Methods of treating disorders, including neurological disorders, by administration of these compositions are described.
PCT/US2023/077879 2022-10-26 2023-10-26 N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof Ceased WO2024092106A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2023367107A AU2023367107A1 (en) 2022-10-26 2023-10-26 N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
CA3267555A CA3267555A1 (en) 2022-10-26 2023-10-26 Compositions of N-N-dimethyltryptamine (DMT) analogues and DMT, their manufacturing processes and their methods of use
EP23883743.9A EP4608395A2 (en) 2022-10-26 2023-10-26 N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/974,443 US20230136824A1 (en) 2021-04-26 2022-10-26 N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
US17/974,443 2022-10-26

Publications (2)

Publication Number Publication Date
WO2024092106A2 WO2024092106A2 (en) 2024-05-02
WO2024092106A3 true WO2024092106A3 (en) 2024-06-06

Family

ID=90832092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/077879 Ceased WO2024092106A2 (en) 2022-10-26 2023-10-26 N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof

Country Status (6)

Country Link
EP (1) EP4608395A2 (en)
AR (1) AR130877A1 (en)
AU (1) AU2023367107A1 (en)
CA (1) CA3267555A1 (en)
TW (1) TW202423415A (en)
WO (1) WO2024092106A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc New compositions of pharmaceutical substances and preparations
MX2023013928A (en) 2021-05-25 2023-12-08 Atai Therapeutics Inc NEW SALTS AND CRYSTALLINE FORMS OF N,N-DIMETHYLTRYPTAMINE SALTS.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
US20210346347A1 (en) * 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
WO2022061242A1 (en) * 2020-09-20 2022-03-24 Tactogen Inc Advantageous tryptamine compositions for mental disorders or enhancement
US20220267267A1 (en) * 2020-06-12 2022-08-25 Beckley Psytech Lmited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
US20220304980A1 (en) * 2019-07-04 2022-09-29 SW Holdings, Inc Metered dosing compositions and methods of use of psychedelic compounds
US20220339139A1 (en) * 2021-04-26 2022-10-27 ATAI Life Sciences AG Novel n,n-dimethyltryptamine compositions and methods

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220304980A1 (en) * 2019-07-04 2022-09-29 SW Holdings, Inc Metered dosing compositions and methods of use of psychedelic compounds
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
US20210346347A1 (en) * 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
US20220267267A1 (en) * 2020-06-12 2022-08-25 Beckley Psytech Lmited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
WO2022061242A1 (en) * 2020-09-20 2022-03-24 Tactogen Inc Advantageous tryptamine compositions for mental disorders or enhancement
US20220339139A1 (en) * 2021-04-26 2022-10-27 ATAI Life Sciences AG Novel n,n-dimethyltryptamine compositions and methods

Also Published As

Publication number Publication date
AR130877A1 (en) 2025-01-29
CA3267555A1 (en) 2024-05-02
AU2023367107A1 (en) 2025-03-27
WO2024092106A2 (en) 2024-05-02
TW202423415A (en) 2024-06-16
EP4608395A2 (en) 2025-09-03

Similar Documents

Publication Publication Date Title
WO2024092106A3 (en) N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
AU727851B2 (en) Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
CN1310908C (en) Rapamycin 29-enols
CA2688708A1 (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO1993006826A1 (en) Composition comprising s-oxiracetame for use as nootropic
HUP0203870A2 (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
CA2492081A1 (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
JP2010539179A5 (en)
WO2005000863A3 (en) 6, 11-4c-bicyclic 9a-azalide derivatives
US20110044917A1 (en) Dental composition for treating peri-implantitis
CA2306393A1 (en) Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization
JP2016196493A (en) Use of L-butylphthalide in the manufacture of a medicament for preventing and treating cerebral ischemic disease
EP1101769A3 (en) Nitrogen containing erythromycin derivatives
ZA202309001B (en) Abhd6 antagonist
AU2006226390B2 (en) Benzamidine derivatives for treatment and prevention of cancer therapy induced mucositis
JP2006510740A5 (en)
AU2024283382A1 (en) Anti-hiv compounds
WO2024145663A3 (en) Salt forms of r-mdma and methods using the same
WO2024107783A3 (en) Novel macrocyclic chalcone-amide derived antiviral agents
WO2006065743A3 (en) Tetracylic bicyclolides
HUP0200655A2 (en) Use of osanetant in the production of medicaments used to treat mood disorders
US7807655B2 (en) Use of pyrimidine nucleotides for the treatment of affections of the peripheral nervous system
JP2005512979A5 (en)
MX2023010797A (en) Anitiviral prodrugs of entecavir (etv) and formulations thereof.
JPH0522717B2 (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23883743

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: AU2023367107

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2023367107

Country of ref document: AU

Date of ref document: 20231026

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2025522970

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025522970

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2023883743

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23883743

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2023883743

Country of ref document: EP

Effective date: 20250526

WWP Wipo information: published in national office

Ref document number: 2023883743

Country of ref document: EP